COMMD9

Across TCGA pan-cancer cohorts, COMMD9 RNA differs between tumor and matched normal tissue in 12 of 18 cancer types tested, making tumor–normal expression one of COMMD9’s most consistent transcriptional readouts.

The strongest signal is observed in liver hepatocellular carcinoma (LIHC), where COMMD9 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types COMMD9 is over-expressed in tumor, although a few such as KICH and LUSC show the opposite, repressed pattern.

LIHC, BLCA, and HNSC are the cancer types where COMMD9 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in COMMD9 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LIHC	Male	All	+0.821	<.001	9	view →
BLCA	All	All	+0.721	<.001	9	view →
HNSC	Male	III,IV	+0.489	<.001	9	view →
KICH	Male	All	−0.935	<.001	8	view →
STAD	All	II,III,IV	+0.643	<.001	8	view →
COAD	All	II,III,IV	+0.394	<.001	8	view →
UCEC	All	All	+0.660	<.001	6	view →
CHOL	Female	All	+1.496	<.001	5	view →
KIRC	Female	All	+0.240	.005	5	view →
LUSC	All	All	−0.171	.013	3	view →
THCA	All	IV	−0.317	.004	2	view →
BRCA	All	III,IV	+0.263	.015	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 12 lineages.

COMMD9–LIHC

Open the LIHC breakdown →